Urine markers predict early fluid restriction nonresponse in SIAD

Fluid restriction is first-line therapy for hyponatremia caused by the syndrome of inappropriate antidiuresis (SIAD), but sodium correction is often inadequate. A predefined secondary analysis of a prospective, multicenter randomized trial enrolling patients with plasma sodium <130 mmol/L assessed proposed predictors of nonresponse. Of 839 patients with SIAD, 229 received fluid restriction within the first 24 hours and had complete laboratory data. Response was defined as a plasma sodium increase >3 mmol/L within 24 hours.

Overall, 86 patients (38%) responded and 143 (62%) did not. Higher urine osmolality and higher baseline plasma sodium were independently associated with nonresponse in multivariable analysis. Urine osmolality >500 mOsm/kg had 78% specificity and a positive likelihood ratio of 1.68; urine sodium >130 mmol/L had 97% specificity and a positive likelihood ratio of 3.81. Combining both thresholds yielded a positive likelihood ratio of 9.62 and a positive predictive value of 94%.

These markers may help identify patients unlikely to achieve early sodium correction with fluid restriction. The authors suggest considering earlier second-line treatment in patients meeting both thresholds. However, this analysis assessed prediction rather than the benefits of marker-guided treatment, included only a subset of the SIAD cohort, and measured response over 24 hours. The abstract does not report sensitivity or confidence intervals for the combined thresholds.